Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Public company · Revenue DKK 40M · -213.70% margin · -DKK 77M FCF
DKK 0.13
+DKK 0.00 (+0.38%)
Live · 10:03 PM · Twelve Data
The business is unprofitable at the operating level (-213.70% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 11.2%, still solid. Margins contracted 5.5pp, which offsets some of the top-line progress.
ROIC dropped from -81.44% to -90.99%, capital efficiency is deteriorating. Negative free cash flow of -DKK 77M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
DKK 40M
▲ +11.2% YoY
Net Income (TTM)
-DKK 82M
▼ -20.3% YoY
Op. Margin
-213.70%
▼ -5.5pp YoY
ROIC
-90.99%
▼ -9.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-DKK 77M
▲ +8.2% YoY
Op. Cash Flow (TTM)
-DKK 77M
▲ +7.8% YoY
Net Debt
-DKK 47M
Net Cash Position
Cash & Equiv.
DKK 55M
3Y CAGR: +11.6%
Continue Research
BioPorto A/S (BIOPOR.XCSE)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BioPorto A/S scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
BioPorto A/S scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -213.7% operating margin and a -91.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BIOPOR.XCSE's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.